ストックスクリーナーアプリを入手
2.05
0.49%
-0.01
アフターアワーズ：
2.06
0.01
+0.49%
前日終値:
$2.06
開ける：
$2.09
24時間の取引高:
769.65K
Relative Volume:
0.95
時価総額：
$71.03M
収益：
-
当期純損益:
$-28.85M
株価収益率:
-1.4621
EPS:
-1.4021
ネットキャッシュフロー:
$-25.62M
1週間 パフォーマンス:
-14.23%
1か月 パフォーマンス:
+9.63%
6か月 パフォーマンス:
-39.17%
1年 パフォーマンス:
+14.53%
1日の値動き範囲:
$2.01
$2.139
1週間の範囲:
$2.01
$2.4267
52週間の値動き範囲:
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
名前
Annovis Bio Inc
セクター
電話
484-875-3192
住所
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.05 | 71.37M | 0 | -28.85M | -25.62M | -1.4021 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-10-25 | アップグレード | Maxim Group | Hold → Buy |
| 2023-12-29 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
Annovis Bio Inc (ANVS) 最新ニュース
Annovis Bio, Inc. Common Stock (NY: ANVS - The Chronicle-Journal
Annovis Bio, Inc. 1Q 2026: Net income $(17.61M), EPS $(0.63) — 10-Q Summary - TradingView
Rising R&D and going-concern risk at Annovis Bio (ANVS) as cash falls - Stock Titan
Annovis Bio (NYSE: ANVS) ramps R&D as Phase 3 Alzheimer’s trial advances - Stock Titan
Annovis Bio Releases Q1 2026 Financial Results - AlphaStreet
Annovis Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results - The Manila Times
ANVS Stock Price, Quote & Chart | ANNOVIS BIO (NYSE:ANVS) - ChartMill
TradingKey - TradingKey
Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -
ANVS Technical Analysis | Trend, Signals & Chart Patterns | ANNOVIS BIO (NYSE:ANVS) - ChartMill
ANVS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer’s at Fierce Biotech Week - MEXC Exchange
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 - mydailyrecord.com
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech ... - Herald and News
Number of shareholders of Annovis Bio Inc – FWB:07X - TradingView
Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results - MyChesCo
Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research - TMX Newsfile
ANVS Earnings History & Surprises | EPS & Revenue Results | ANNOVIS BIO (NYSE:ANVS) - ChartMill
Annovis Bio | DEF 14A: Definitive information statements - Moomoo
Annovis Bio (ANVS) seeks approval to expand 2019 equity incentive plan at 2026 meeting - Stock Titan
Annovis Bio (ANVS) price target increased by 13.94% to 15.98 - MSN
Annovis Bio reports positive cognition data in early Alzheimer’s trial - Investing.com UK
Annovis Bio reports positive cognition results in early Alzheimer’s trial By Investing.com - Investing.com Australia
Annovis Bio reports positive cognition data in early Alzheimer’s trial By Investing.com - Investing.com Australia
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio - The Manila Times
Annovis Bio reports positive cognition results in early Alzheimer’s trial - Investing.com
Annovis Bio, Inc. (NYSE:ANVS) Sees Significant Increase in Short Interest - MarketBeat
Annovis Bio Announces Transfer of Listing to the New York Stock Exchange - TMX Newsfile
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease - TMX Newsfile
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022) - TMX Newsfile
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences - TMX Newsfile
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics - TMX Newsfile
Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference - TMX Newsfile
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022 - TMX Newsfile
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging - TMX Newsfile
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference - TMX Newsfile
Traders Buy Large Volume of Annovis Bio Call Options (NYSE:ANVS) - MarketBeat
Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity - Moomoo
Aug Summary: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Fed Watch: Can Annovis Bio Inc disrupt its industry2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Retail Trends: Will Annovis Bio Inc benefit from seasonalityPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Annovis Bio raises $10M to fund Alzheimer’s drug trial By Investing.com - Investing.com Australia
Annovis Bio highlights buntanetap development in published article - MSN
Annovis secures financing for buntanetap’s NDA submission - The Pharma Letter
Annovis Bio raises $10M to fund Alzheimer’s drug trial - Investing.com
A $10M cash boost puts Annovis on track for an Alzheimer’s drug filing - Stock Titan
Annovis Bio Inc (ANVS) 財務データ
収益
当期純利益
現金流量
EPS
2.53%
大文字化:
|
ボリューム (24 時間):